-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, R6XMukuaqlYBTInbX28BY1ZtWEEgRFf9X/JVRVi7qt2+OpAY0paGXJ0ILiWDD3SQ Sc1a2Bgmh/vujmpHW+Xk+g== 0001144204-08-047385.txt : 20080814 0001144204-08-047385.hdr.sgml : 20080814 20080814162856 ACCESSION NUMBER: 0001144204-08-047385 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20080630 FILED AS OF DATE: 20080814 DATE AS OF CHANGE: 20080814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Conmed Healthcare Management, Inc. CENTRAL INDEX KEY: 0000943324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 421297992 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27554 FILM NUMBER: 081019549 BUSINESS ADDRESS: STREET 1: 9375 CHESAPEAKE STREET STREET 2: SUITE 203 CITY: LA PLATA, STATE: MD ZIP: 20646 BUSINESS PHONE: 5152221717 MAIL ADDRESS: STREET 1: 9375 CHESAPEAKE STREET STREET 2: SUITE 203 CITY: LA PLATA, STATE: MD ZIP: 20646 FORMER COMPANY: FORMER CONFORMED NAME: PACE HEALTH MANAGEMENT SYSTEMS INC DATE OF NAME CHANGE: 19960118 10-Q 1 v123111_10q.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 10-Q
 
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended:
 
Commission File Number:
June 30, 2008
 
0-27554
Conmed Healthcare Management, Inc.
(Exact name of small business issuer as specified in its charter)
 
Delaware
 
42-1297992
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer Identification Number)
 
7250 Parkway Dr., Suite 400
Hanover, MD 21076
(Address and zip code of principal executive offices)
 
(410) 567-5520
(Issuer’s telephone -number, including area code)
 
Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject of the filing requirements for at least the past 90 days.
YES x    NO o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated filer o   Accelerated filer o  Non-Accelerated filer o  Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES o    NO x
 
State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
 
 
 
Number of Shares Outstanding
Class
 
August 14, 2008
Common Stock, $0.0001 par value per share
 
12,024,222
 
Transitional Small Business Disclosure Format (Check one):    YES o    NO x



CONMED HEALTHCARE MANAGEMENT, INC.

TABLE OF CONTENTS

 
Page
 
 PART I. FINANCIAL INFORMATION
 
   
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
 
   
Consolidated Balance Sheets
 
June 30, 2008 and December 31, 2007
1
 
 
Consolidated Statements of Operations
 
For the six months ended June 30, 2008, the 156 day period January 26, 2007 to June 30, 2007 , the 25-day period January 1, 2007 to January 25, 2007 (Predecessor) and the three months ended June 30, 2008 and 2007
2
   
Consolidated Statements of Cash Flows
 
For the six months ended June 30, 2008, the 156-day period January 26, 2007 to June 30, 2007 and the 25-day period January 1, 2007 to January 25, 2007 (Predecessor)
3
 
 
Notes to Consolidated Financial Statements
4
 
 
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
12
 
 
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
19
 
 
ITEM 4(T). CONTROLS AND PROCEDURES
19
 
 
PART II. OTHER INFORMATION
 
 
 
ITEM 1. LEGAL PROCEEDINGS
20
 
 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES
20
 
 
ITEM 3. DEFAULT UPON SENIOR SECURITIES
20
 
 
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
20
 
 
ITEM 5. OTHER INFORMATION
20
 
 
ITEM 6. EXHIBITS
20
   
   
SIGNATURES
21



ITEM 1. FINANCIAL STATEMENTS
 
CONSOLIDATED BALANCE SHEETS

   
SUCCESSOR
June 30, 2008
(unaudited)
 
SUCCESSOR
December 31,
2007
 
ASSETS
             
CURRENT ASSETS
             
Cash and cash equivalents
 
$
7,251,819
 
$
7,136,720
 
Accounts receivable
   
1,780,606
   
1,622,424
 
Prepaid expenses
   
542,789
   
214,834
 
Total current assets
   
9,575,214
   
8,973,978
 
PROPERTY AND EQUIPMENT, NET
   
442,380
   
212,815
 
DEFERRED TAXES
   
90,000
   
90,000
 
OTHER ASSETS
             
Service contracts acquired, net
   
2,105,000
   
2,699,000
 
Non-compete agreements, net
   
715,000
   
749,000
 
Goodwill
   
5,068,388
   
4,852,338
 
Deposits
   
13,698
   
58,698
 
Total other assets
   
7,902,086
   
8,359,036
 
   
$
18,009,680
 
$
17,635,829
 
               
LIABILITIES AND SHAREHOLDERS’ EQUITY
             
CURRENT LIABILITIES
             
Accounts payable
 
$
997,100
 
$
837,144
 
Accrued expenses
   
2,590,453
   
1,563,020
 
Taxes payable
   
5,000
   
5,000
 
Deferred revenue
   
26,247
   
353,075
 
Notes payable, current portion
   
73,784
   
7,798
 
Total current liabilities
   
3,692,584
   
2,766,037
 
NOTES PAYABLE, LONG-TERM
   
35,777
   
5,418
 
SHAREHOLDERS’ EQUITY
             
Preferred stock no par value; authorized 5,000,000 shares; issued and outstanding zero shares as of June 30, 2008
   
   
 
Common stock, $0.0001 par value, authorized 40,000,000 shares; issued and outstanding 12,024,222 shares as of June 30, 2008
   
1,202
   
1,194
 
Additional paid-in capital
   
36,365,126
   
35,901,874
 
Retained (deficit)
   
(22,085,009
)
 
(21,038,694
)
Total shareholders' equity
   
14,281,319
   
14,864,374
 
   
$
18,009,680
 
$
17,635,829
 
 
See Notes to unaudited Financial Statements

Page - 1 -


CONMED HEALTHCARE MANAGEMENT, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) 

 
 
SUCCESSOR 
For the Six
Months Ended
June 30, 2008
 
SUCCESSOR
For the Period
January 26,
2007 to June 
30, 2007 
 
PREDECESSOR 
For the Period
January 1,
2007 to
January 25
2007
 
 SUCCESSOR
For the Three
Months Ended
June 30, 2008
 
SUCCESSOR
For the Three
Months Ended
June 30, 2007
 
                        
Service contract revenue
 
$
16,831,113
 
$
10,015,594
 
$
1,504,565
 
$
8,994,863
 
$
5,969,220
 
                                 
HEALTHCARE EXPENSES:
                               
Salaries, wages and employee benefits
   
8,719,760
   
4,995,851
   
842,575
   
4,605,733
   
3,093,425
 
Medical expenses
   
4,659,923
   
2,680,219
   
439,206
   
2,643,335
   
1,505,682
 
Other operating expenses
   
487,704
   
411,685
   
45,552
   
254,269
   
246,619
 
Total healthcare expenses
   
13,867,387
   
8,087,755
   
1,327,333
   
7,503,337
   
4,845,726
 
                                 
Gross profit
   
2,963,726
   
1,927,839
   
177,232
   
1,491,526
   
1,123,494
 
                                 
Selling and administrative expenses
   
3,084,421
   
2,045,301
   
92,264
   
1,495,409
   
1,178,286
 
Depreciation and amortization
   
1,029,575
   
1,071,652
   
1,698
   
530,126
   
572,409
 
Total operating expenses
   
4,113,996
   
3,116,953
   
93,962
   
2,025,535
   
1,750,695
 
                                 
Operating income (loss)
   
(1,150,270
)
 
(1,189,114
)
 
83,270
   
(534,009
)
 
(627,201
)
                                 
INTEREST INCOME (EXPENSE)
                               
Interest income
   
107,150
   
143,943
   
287
   
41,253
   
84,193
 
Interest (expense)
   
(3,194
)
 
(422
)
 
(93
)
 
(1,504
)
 
(244
)
Total interest income
   
103,956
   
143,521
   
194
   
39,749
   
83,949
 
                                 
Income (loss) before income taxes
   
(1,046,314
)
 
(1,045,593
)
 
83,464
   
(494,260
)
 
(543,252
)
Income tax benefit
   
   
(291,000
)
 
   
   
(168,000
)
Net income (loss)
 
$
(1,046,314
)
$
(754,593
)
$
83,464
 
$
(494,260
)
$
(375,252
)
                                 
LOSS PER COMMON SHARE
                               
Basic and diluted
 
$
(0.09
)
$
(0.09
)
       
(0.04
)
 
(0.03
)
                                 
WEIGHTED-AVERAGE SHARES OUTSTANDING
                               
Basic and diluted
   
12,006,848
   
8,389,615
         
12,024,222
   
11,833,356
 

See Notes to unaudited Financial Statements

Page - 2 -


CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

   
SUCCESSOR 
For the Six Months
Ended June 30,
2008
 
SUCCESSOR 
For the Period
January 26, 2007
to June 30, 2007
 
PREDECESSOR 
For the Period
January 1, 2007 to
January 25, 2007
 
CASH FLOWS FROM OPERATING ACTIVITIES
                   
Net income (loss)
 
$
(1,046,314
)
$
(754,593
)
$
83,464
 
Adjustments to reconcile net income to net cash provided by operating activities
                   
Depreciation
   
39,575
   
14,652
   
1,698
 
Amortization
   
990,000
   
1,057,000
   
 
Stock-based compensation
   
263,246
   
299,449
   
 
Loss on disposal of property
   
2,257
   
   
 
Deferred income taxes
   
   
(376,000
)
 
 
Changes in working capital components
                   
Decrease (increase) in accounts receivable
   
(158,182
)
 
(264,283
)
 
197,327
 
(Increase) in claims against escrow
   
   
(333,373
)
 
 
Decrease (increase) in prepaid expenses
   
(327,955
)
 
(32,571
)
 
30,687
 
Decrease in deposits
   
45,000
   
   
 
Increase in accounts payable
   
159,956
   
146,558
   
258,562
 
Increase (decrease) in accrued expenses
   
1,027,433
   
643,374
   
(469,320
)
(Decrease) in deferred revenue
   
(326,828
)
 
(49,521
)
 
(29,155
)
Net cash provided by operating activities
   
668,188
   
350,692
   
73,263
 
                     
CASH FLOWS FROM INVESTING ACTIVITIES
                   
Purchase of property and equipment
   
(271,397
)
 
(37,313
)
 
 
Asset Purchase from EMDC, P.C.
   
(245,762
)
 
   
 
Acquisition of Conmed, Inc., net of cash acquired
   
   
(7,675,097
)
 
 
Net cash used in investing activities
   
(517,159
)
 
(7,712,410
)
 
 
                     
CASH FLOWS FROM FINANCING ACTIVITIES
                   
Short-term borrowings
   
   
289,368
   
 
Payments on loans
   
(35,930
)
 
(134,307
)
 
(594
)
Net proceeds from Private Placement
   
   
13,085,649
   
 
Proceeds from exercise of warrants
   
   
33,000
   
 
Net cash provided by (used in) financing activities
   
(35,930
)
 
13,273,710
   
(594
)
                     
Net increase in cash and cash equivalents
   
115,099
   
5,911,992
   
72,669
 
                     
CASH AND CASH EQUIVALENTS
                   
Beginning
   
7,136,720
   
662,305
   
122,269
 
Ending
 
$
7,251,819
 
$
6,574,297
 
$
194,938
 
                     
NON-CASH INVESTING AND FINANCING ACTIVITIES WERE AS FOLLOWS:
                   
Escrow payments on Acquisition in prior periods
 
$
 
$
500,000
 
$
 
Stock (81,081 Shares) for Asset Purchase from EMDC, P.C.
   
150,000
   
   
 
Promissory Note payable to EMDC, P.C. for Asset Purchase
   
132,275
   
   
 
Warrants (80,000 Shares) for Asset Purchase from EMDC, P.C.
   
50,013
   
   
 
Acquisition expenses paid in prior periods
   
   
239,935
   
 
Private Placement expenses paid in prior periods
   
   
148,652
   
 
Income tax claims receivable related to tax benefit received from the exercise of warrants
   
   
85,000
   
 
Deferred tax effect related to tax benefit received from the exercise of warrants
   
   
61,000
   
 
   
$
332,288
 
$
1,034,587
 
$
 
                     
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
                   
Cash payments for interest
 
$
3,194
 
$
422
 
$
93
 
Income taxes paid
   
   
85,000
   
 

See Notes to unaudited Financial Statements

Page - 3 -


 
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 
 
NOTE 1.  Nature of Business
 
Nature of Business
Prior to January 26, 2007, Conmed Healthcare Management, Inc. and its subsidiaries (the "Company") formerly known as Pace Health Management Systems, Inc. traded under the symbol "PCES", was classified as a public shell, had no ongoing operations, minimal operating expenses and no employees.

On January 26, 2007, the Company acquired Conmed, Inc. ("Conmed, Inc.") a provider of correctional healthcare services (the "Acquisition"). Conmed, Inc. was formed as a corporation on June 10, 1987 in the State of Maryland for the purpose of providing healthcare services exclusively to county detention centers located in Maryland. As Conmed, Inc. developed, it accepted more contracts for additional services including mental health, pharmacy and out-of-facility healthcare expenses. In 2000, Conmed, Inc. served more than 50% of the county detention healthcare services market in Maryland. In 2003, Conmed, Inc. elected to seek contracts outside of Maryland.

As a result of the Acquisition, Conmed, Inc. is a wholly-owned subsidiary of the Company and the business of Conmed, Inc. is now our primary business. As of June 30, 2008, we were in contract with, and currently providing medical services in thirty counties in five states including: Kansas, Maryland, Oregon, Virginia and Washington.

On March 13, 2007, the Company changed its name to Conmed Healthcare Management, Inc.

The amounts shown in the Consolidated Statements of Operations and Cash Flows for the 25-day period from January 1, 2007 to January 25, 2007 are all Conmed, Inc. pre-Acquisition amounts and hence are designated as PREDECESSOR amounts. The amounts for the 156-day period from January 26, 2007 to June 30, 2007 are after the Acquisition and reflect the combined activities of Conmed, Inc. and Conmed Healthcare Management, Inc. from the date of Acquisition and, as a result, these amounts are designated as SUCCESSOR amounts. The Consolidated Balance Sheet includes the consolidated amounts of Conmed Healthcare Management, Inc., Conmed, Inc. and Conmed Oregon, Inc. as of June 30, 2008 and December 31, 2007 and, as a result, are designated as SUCCESSOR amounts.

Reclassifications 
Certain reclassifications have been made to the PREDECESSOR amounts to conform to current presentation of the financial statements.
 
NOTE 2.  Significant Accounting Policies
 
The accompanying unaudited consolidated financial statements contained herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for interim reporting requirements of Form 10-Q and Item 310(b) of Regulation S-B. Accordingly, the financial information and disclosures normally included in the financial statements prepared annually in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America have been condensed or omitted. Readers of this report should, therefore, refer to the consolidated financial statements and notes included in our Annual Report of Form 10-KSB for the year ended December 31, 2007, filed with the Securities and Exchange Commission on March 31, 2008.

In the opinion of management, all adjustments (consisting of normal and recurring adjustments) which are considered necessary to fairly present our financial position and our results of operations as of and for these periods have been made.

Our interim results of operations for the six months ended June 30, 2008 are not necessarily indicative of the results of operations to be expected for a full year.

Page - 4 -


A summary of the Company's significant accounting policies is as follows:

Accounting Estimates and Assumptions
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our methods of revenue recognition from contracts are based primarily on estimates as are accrued expenses. Actual results could differ from those estimates.

Acquisition
The Acquisition of Conmed, Inc. was recorded based on FASB Statement No. 141, ("SFAS 141") Business Combinations, using the purchase method. Under purchase accounting, assets acquired should be stated on the financial statements at "fair value" (see definition in Standard of Value section below). SFAS 141 requires that intangible assets be recognized as assets apart from goodwill if they meet one of two criteria, (1) the contractual-legal criterion, or (2) the separability criterion. SFAS 141 also requires disclosure of the primary reasons for business combination and the allocation of the purchase price paid to the assets acquired and the liabilities assumed by major balance sheet caption.

We employed an independent valuation firm to assist management in the identification of the intangible assets acquired and in estimating the fair value of those assets. Estimates of the fair value of the identifiable intangible assets acquired in the Acquisition as of January 26, 2007, are as follows:

Asset
 
Fair Value
 
Service contracts acquired
 
$
4,500,000
 
Non-compete agreements
   
1,000,000
 
Goodwill
   
4,852,338
 
Total
 
$
10,352,338
 

Asset Purchase
On February 29, 2008, the Company completed the purchase of EMDC, P.C.. The Asset Purchase was recorded based on FASB Statement No. 141, ("SFAS 141") Business Combinations, using the purchase method. Under purchase accounting, assets acquired should be stated on the financial statements at "fair value" (see definition in Standard of Value section below). SFAS 141 requires that intangible assets be recognized as assets apart from goodwill if they meet one of two criteria, (1) the contractual-legal criterion, or (2) the separability criterion. SFAS 141 also requires disclosure of the primary reasons for business combination and the allocation of the purchase price paid to the assets acquired and the liabilities assumed by major balance sheet caption.

Estimates of the fair value of the identifiable intangible assets acquired in the Asset Purchase as of February 29, 2008, are as follows:

Asset
 
Fair Value
 
Service contracts acquired
 
$
242,000
 
Non-compete agreements
   
120,000
 
Goodwill
   
216,050
 
Total
 
$
578,050
 

Net Cash Paid
     
Purchase Price
 
$
578,050
 
Stock Issued
   
(150,000
)
Note Issued
   
(132,275
)
Warrants Issued
   
(50,013
)
Total
 
$
245,762
 

The Company has an adjustable note payable in connection with the Asset Purchase from EMDC, P.C., for $140,000. The note requires monthly payments of $5,833 including interest at 0%, as such, the note is recorded at its present value, using an imputed 6% interest rate, of $132,275. On February 1, 2009, the remaining balance owed shall be adjusted, up or down, based on the performance of the Company’s Northwest Operating Territory.

Page - 5 -


Service Contracts Acquired
There are material costs in obtaining a customer list, especially customers with recurring revenue streams. The value of service contracts acquired is represented by the future revenue streams, therefore, the Income Approach is the most applicable fair value measurement approach to value these assets. The operating income streams of service contracts acquired was calculated based on net present value of estimated earnings at an interest rate of 20%. Operating income streams were estimated on a contract by contract basis and an overall cost factor was used to estimate management expenses. Service contracts acquired are amortized over the life of each individual contract, ranging from approximately one to four years.

Projected amortization of service contracts for the next four years:
 
For the Twelve Months 
ended June 30,
 
Amortization
 
2009
   
1,449,000
 
2010
   
462,000
 
2011
   
173,000
 
2012
   
21,000
 
   
$
2,105,000
 

Accumulated amortization of service contracts as of June 30, 2008 and 2007 was $2,637,000 and $941,000, respectively.

Service contract amortization expense recognized was approximately $836,000, $941,000 and $0 for the six months ending June 30, 2008, the 156-day period ending June 30, 2007 and the 25-day period ending January 25, 2007, respectively.

Non-Compete Agreements
Non-compete agreements are generally acquired as part of our acquisition agreements. Key considerations in estimating the value of non-compete agreements include consideration of the potential losses resulting from such competition, the enforceability of the terms of the agreement, and the likelihood of competition in the absence of the agreement. Non-compete agreements are amortized over the lives of the agreements, approximately two to four years.

Projected amortization of non-compete agreements for the next four years:

For the Twelve Months 
ended June 30,
 
Amortization
 
2009
 
$
329,000
 
2010
   
285,000
 
2011
   
101,000
 
2012
   
 
   
$
715,000
 

Accumulated amortization of non-compete agreements as of June 30, 2008 and 2007 was $405,000 and $116,000, respectively.
 
Non-compete amortization expense recognized was approximately $154,000, $116,000 and $0 for the six months ending June 30, 2008, the 156-day period ending June 30, 2007 and the 25-day period ending January 25, 2007, respectively.

Page - 6 -


Goodwill: 
We recorded as goodwill the excess of purchase price over the fair value of the identifiable net assets acquired. SFAS No. 142, Goodwill and Other Intangible Assets, prescribes a two-step process for impairment testing of goodwill, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. Since creation of the goodwill there have been no indicators of impairment. We have elected to perform our annual analysis during the fourth quarter of each fiscal year.

Fair Value of Financial Instruments
Financial instruments include cash, receivables, accounts payable, accrued expenses, deferred revenue and long-term debt. We believe the fair value of each of these instruments approximates their carrying value in the balance sheet as of the balance sheet date. The fair value of current assets and current liabilities is estimated to approximate carrying value due to the short-term nature of these instruments. The fair value of the long-term debt is estimated based on anticipated interest rates which we believe would currently be available to us for similar issues of debt, taking into account our current credit risk and the other market factors.

Effective January 1, 2008, the Company adopted Statement of Financial Accounting Standard No. 157, or SFAS 157, “Fair Value Measurements”. In February 2008, the Financial Accounting Standards Board, or FASB, issued FASB Staff Position No. FAS 157-2, “Effective Date of FASB Statement No. 157”, which provides a one year deferral of the effective date of SFAS 157 for non-financial assets and non-financial liabilities, except those that are recognized or disclosed in the financial statements at fair value at least annually. Therefore, the Company has adopted the provisions of SFAS 157 with respect to its financial assets and liabilities only. SFAS 157 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under SFAS 157 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under SFAS 157 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:
 
 
·
Level 1 – Quoted prices in active markets for identical assets or liabilities.
 
 
·
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
 
·
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The adoption of SFAS 157 had no material effect to the financials or related disclosure.

Effective January 1, 2008, the Company adopted SFAS No. 159 “The Fair Value Option for Financial Assets and Financial Liabilities”, or SFAS 159. SFAS 159 allows an entity the irrevocable option to elect fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect the fair value option under this Statement to specific assets or liabilities.

Principles of Consolidation:
The consolidated financial statements include the accounts of the Company and our wholly owned subsidiaries, Conmed, Inc and Conmed Oregon, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition
Our principal source of revenue are contracts to provide medical assistance to state and local correctional facilities. Deferred revenue represents amounts that may be paid in advance of delivery under these contracts.

Most of our contracts call for a fixed monthly fee. In addition, most contracts have incremental charges based on the average daily population ("ADP") of the correctional facility or a contractual fee adjustment based on the ADP. Revenues from contracts are recognized ratably for fixed fees, or monthly for contracts with variable charges based on ADP. We have one contract that partially operates on a cost plus basis. The timing of each payment varies per contract. Credit terms are not more than 30 days from the date of invoice.

Page - 7 -


Certain contracts include "stop/loss" limits, which create a ceiling to our financial responsibility for an individual inmate's care or a maximum amount in the aggregate for certain categories of medical expenses, whereby we are protected from catastrophic medical losses. In circumstances where a stop/loss is reached, we are reimbursed for any costs incurred over the predetermined stop/loss amount. Any reimbursement received by us is recorded as revenue. During the six month period ended June 30, 2008, the 156-day period ended June 30, 2007, and the 25-day period ended January 25, 2007, we received stop/loss reimbursements of approximately $475,000, $127,000 and $15,000, respectively, which were included in revenue.

Accrued Medical Claims Liability
Medical expenses include the costs associated with medical services provided by off-site medical providers; pharmacy, laboratory and radiology fees; professional and general liability insurance as well as other generally related medical expenses. The cost of medical services provided, administered or contracted for are recognized in the period in which they are provided based in part on estimates for unbilled medical services rendered through the balance sheet date. The Company estimates an accrual for unbilled medical services using available utilization data including hospitalization, one-day surgeries, physician visits and emergency room and ambulance visits and other related costs, which are estimated. Additionally, Company personnel review certain inpatient hospital stays and other high cost medical procedures and expenses in order to attempt to identify costs in excess of the historical average rates. Once identified, reserves are determined which take into consideration the specific facts available at that time.

Actual payments and future reserve requirements will differ from the Company’s current estimates. The differences could be material if significant adverse fluctuations occur in the healthcare cost structure or the Company’s future claims experience. Changes in estimates of claims resulting from such fluctuations and differences between estimates and actual claims payments are recognized in the period in which the estimates are changed or the payments are made.

Stock Compensation
Effective January 1, 2006, we adopted SFAS No. 123 Revised, Shared-Based Payments ("SFAS 123R"), using the modified prospective transition method. Prior to that date, we accounted for stock option awards under Accounting Principles Board Opinion No. 25. In accordance with SFAS 123R, compensation expense for stock-based awards is recorded over the vesting period at the fair value of the award at the time of grant. The recording of such compensation began on January 1, 2006 for shares not yet vested as of that date and for all new grants subsequent to that date. We recognized stock-based compensation expense of approximately $263,000, $299,000 and $0 for the six months ended June 30, 2008, the 156-day period ended June 30, 2007 and the 25-day period ended January 25, 2007, respectively. The exercise price of options granted under our incentive plans is equal to the fair market value of the underlying stock at the grant date. We assume no projected forfeitures on its stock-based compensation, since actual historical forfeiture rates on our stock-based incentive awards have been negligible.

Income Taxes
Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Basic and Diluted Loss Per Share
We have adopted SFAS No. 128, Earnings per Share ("SFAS 128"), which requires us to present basic and diluted income (loss) per share amounts. Basic income (loss) per share is based on the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is based on the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares consist of stock options and warrants (using the treasury stock method) and convertible preferred stock (using the if-converted method).

Page - 8 -


New Accounting Pronouncements
In December 2007, the FASB issued SFAS No. 141(Revised) ("SFAS 141R"), Business Combinations. SFAS 141R replaces the original SFAS No. 141. This statement applies to all transactions in which an entity obtains control of one or more businesses. SFAS 141R requires an acquirer to recognize the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at their fair values, with limited exceptions, as of the acquisition date. Goodwill is to be recognized as a residual. If the acquisition-date fair value exceeds the consideration transferred, a gain is to be recognized. The Statement generally requires that acquisition costs be expensed. This Statement is effective for business combinations for which the acquisition date is on or after January 1, 2009. We do not expect the adoption of this Statement will have a material impact on our financial position or results of operations.

In December 2007, the FASB issued SFAS No. 160 ("SFAS 160"), Noncontrolling Interests in Consolidated Financial Statements. SFAS 160 requires companies to report ownership interest in subsidiaries held by other parties (minority interest) be clearly identified, labeled and presented in the consolidated statement of financial condition separately within the equity section. The amount of consolidated net income attributable to the parent company and to the noncontrolling interest is to be clearly identified and presented on the face of the consolidated statement of income. The Statement is effective beginning January 1, 2009. We do not expect the adoption of this Statement will have a material impact on our financial position or results of operations.

Presentation of share and Per Share Information
All common stock shares and per share information has been adjusted to reflect the 1 for 20 reverse stock split effective on March 14, 2007.
 
NOTE 3.  Common Stock Warrants and Options
 
Common Stock Warrants
For the six months ended June 30, 2008, warrant activity is as follows.
 
Warrants @ $1.65 per share
In connection with a consulting agreement, we issued to a consultant, a warrant to purchase 120,000 shares of common stock at an exercise price of $1.65 per share expiring February 24, 2013. The warrants will vest over four (4) years and are contingent upon the continued service to the Company of the warrant holder. 30,000 warrants will vest on February 24, 2009 and 2,500 warrants will vest on the 24th of each calendar month thereafter for the following 36 months or until such time as the warrant holder is no longer providing service for the Company. The warrants were valued at $66,909 as of the date of grant using the fair value method which will be recorded as stock-based compensation over the vesting period.

As of June 30, 2008, no warrants have been exercised and 120,000 warrants remain outstanding.

Warrants @ $1.85 per share
In connection with the asset purchase from EMDC, P.C., we issued to two consultants, warrants to purchase 80,000 shares of common stock at an exercise price of $1.85 per share. The warrants vest immediately and expire February 28, 2013. The warrants were valued at $50,013 as of the date of grant using the fair value method. This expense has been included in goodwill as deal costs.

As of June 30, 2008, no warrants have been exercised and 80,000 warrants remain outstanding.

Summary
During the six months ended June 30, 2008, the 156-day period ended June 30, 2007, and the 25-day period ended January 25, 2007, we recorded stock-based compensation expense net of reversals for forfeited warrants totaling $14,197, $0 and $0, respectively.

As of June 30, 2008, we have outstanding warrants to purchase an aggregate of 2,605,000 shares of common stock at an average exercise price of $1.11 and have reserved shares of our common stock for issuance in connection with the potential exercise thereof. During the six months ended June 30, 2008, no warrants were exercised.

Page - 9 -


Common Stock Options
The Board of Directors has adopted, and our stockholders have approved, the 2007 Stock Option Plan (the "2007 Plan"). The 2007 Plan provides for the grant of 1,600,000 (post-Plan of Recapitalization) incentive stock options, nonqualified stock options, restricted stock, stock bonuses and stock appreciation rights. On May 29, 2008, the 2007 Plan was amended to increase the total number of shares available to 2,350,000. The 2007 Plan is administered by the Board of Directors, which has the authority and discretion to determine: the persons to whom the options will be granted; when the options will be granted; the number of shares subject to each option; the price at which the shares subject to each option may be purchased; and when each option will become exercisable. The options generally vest over three to four years and expire no later than ten years from the date of grant.

During the six months ended June 30, 2008, the 156-day period ended June 30, 2007, and the 25-day period ended January 25, 2007, we recorded stock-based compensation expense net of reversals for forfeited options totaling $249,050, $299,449 and $0, respectively.

During the six months ended June 30, 2008, the Board of Directors authorized options to purchase 112,500 of common stock at an average exercise price of $2.26 per share. Additionally, during the six months ended June 30, 2008, 43,750 shares were forfeited and as of June 30, 2008, 617,583 remaining shares are available for grant.
 
NOTE 4.  Accrued Expenses
 
A summary of accrued expenses is as follows:
 
   
SUCCESSOR
June 30, 2008
 
SUCCESSOR
June 30, 2007
 
Accrued salaries and employee benefits
 
$
1,218,843
 
$
813,434
 
Accrued medical claims liability
   
1,274,530
   
528,665
 
Other
   
97,080
   
10,117
 
Total accrued expenses
 
$
2,590,453
 
$
1,352,216
 
 
NOTE 5.  Earnings Per Share
 
The following table sets forth the computation of basic and diluted (loss) per-share:
 
   
SUCCESSOR 
For the Six
Months Ended
June 30, 2008
 
SUCCESSOR
For the Period
January 26, 2007
to June 30, 2007
 
PREDECESSOR
For the Period
January 1, 2007 to
January 25, 2007
 
Net income (loss)
 
$
(1,046,314
)
$
(754,593
)
$
83,464
 
Weighted average shares outstanding
   
12,024,222
   
8,389,615
   
 
Income (loss) per common share
 
$
(0.09
)
$
(0.09
)
     
 
Common stock warrants and options outstanding totaling 4,337,417 shares are not included in diluted earnings per common share as they would have an antidilutive effect upon earnings per common share.

Page - 10 -

 
NOTE 6.  Major Customers and Commitments
 
During the six months ended June 30, 2008, the 156-day period ended June 30, 2007 and the 25-day period ended January 25, 2007, we had approximate sales with major customers and related approximate receivables as follows:

   
SUCCESSOR
For the Six Months ended June
30, 2008
 
SUCCESSOR
For the Period January 26, 2007 to
June 30, 2007
 
PREDECESSOR
For the Period January 1, 2007 to
January 25, 2007
 
   
Revenue
 
Accounts 
Receivable
 
Revenue
 
Accounts 
Receivable
 
Revenue
 
Accounts 
Receivable
 
Company A 
 
$
3,066,000
 
$
41,000
 
$
2,548,000
 
$
 
$
374,000
 
$
26,000
 
Company B
   
2,080,000
   
349,000
   
1,532,000
   
242,000
   
240,000
   
 
Company C
   
1,446,000
   
247,000
   
   
   
   
 
Company D
   
1,305,000
   
221,000
   
687,000
   
127,000
   
103,000
   
127,000
 
Company E
   
1,077,000
   
223,000
   
866,000
   
150,000
   
135,000
   
173,000
 
Company F
   
836,000
   
95,000
   
   
   
   
 

In connection with our normal contract activities, we are required to acquire performance and payment bonds for certain service contracts. The surety issuing the bonds has recourse against certain assets in the event the surety is required to honor the bonds. The lengths of our bond contracts vary. Most contracts are one year or less, but periodically contracts are obtained which exceed one year. At June 30, 2008, the Company had $9,560,061 in outstanding bonds.
 
NOTE 7.  Income Tax Matters
 
Management applied a valuation allowance against certain deferred tax assets because of a limited history of taxable income, the long-term nature of the deferred tax asset and certain limitations regarding the utilization of the net operating loss carryforwards. No tax benefit has been recognized for the loss from operations for the six months ended June 30, 2008.

Page - 11 -

 
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
 
Information included in this section contains forward-looking statements regarding the business, operations and financial condition of both the Company and Conmed, Inc. within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from our future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend," “plan,” “potential” or "project" or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that these projections included in these forward-looking statements will come to pass. The Company’s actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. The Company cautions you not to place undue reliance on these forward-looking statements. Such forward-looking statements relate only to events as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized. You are advised, however, to consult any further disclosures the Company makes in future public statements and press releases.

General
 
Prior to January 26, 2007, the Company was classified as a public shell and had no ongoing operations, minimal operating expenses, no employees and operated under the name Pace Healthcare Management Systems, Inc. (“Pace”).

On January 26, 2007, the Company acquired Conmed, Inc. (“Conmed Inc.”), a provider of correctional healthcare services since 1984 the (“Acquisition”). Conmed Inc. was formed as a corporation on June 10, 1987 in the State of Maryland for the purpose of providing healthcare services exclusively to county detention centers located in Maryland. As Conmed Inc. developed, it accepted more contracts for additional services including pharmacy and out-of-facility healthcare expenses. In 2000, Conmed, Inc. served more than 50% of the county detention healthcare services market in Maryland. In 2003, Conmed, Inc. elected to seek contracts outside of Maryland and by June 2007 it had secured contracts in Kansas, Oregon, Virginia and Washington. Conmed, Inc. was in contract with and serviced 21 detention centers and facilities at the county level in the United States. As a result of the Acquisition, Conmed, Inc. is a wholly-owned subsidiary of the Company and the business of Conmed, Inc. is now our primary business.
 
Critical Accounting Policies
 
The discussion and analysis of our financial condition and results of operations are based upon our condensed financial statements. These condensed financial statements have been prepared following the requirements of accounting principles generally accepted in the United States (“GAAP”) for interim periods and require us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition and related IBNR and amortization and potential impairment of intangible assets and goodwill and stock-based compensation expense. As these are condensed financial statements, one should also read expanded information about our critical accounting policies and estimates provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in our Form 10-KSB for the year ended December 31, 2007. There have been no material changes to our critical accounting policies and estimates from the information provided in our 10-KSB for the year ended December 31, 2007.

Recently adopted accounting standards

Effective January 1, 2008, the Company adopted Statement of Financial Accounting Standard No. 157, or SFAS 157, “Fair Value Measurements”. In February 2008, the Financial Accounting Standards Board, or FASB, issued FASB Staff Position No. FAS 157-2, “Effective Date of FASB Statement No. 157”, which provides a one year deferral of the effective date of SFAS 157 for non-financial assets and non-financial liabilities, except those that are recognized or disclosed in the financial statements at fair value at least annually. Therefore, the Company has adopted the provisions of SFAS 157 with respect to its financial assets and liabilities only. SFAS 157 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under SFAS 157 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under SFAS 157 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Page - 12 -

 
 
·
Level 1 – Quoted prices in active markets for identical assets or liabilities.
 
 
·
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
 
·
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Effective January 1, 2008, the Company adopted SFAS No. 159 “The Fair Value Option for Financial Assets and Financial Liabilities”, or SFAS 159. SFAS 159 allows an entity the irrevocable option to elect fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect the fair value option under this Statement to specific assets or liabilities.

New Accounting Pronouncements

In December 2007, the FASB issued SFAS No. 141(Revised) ("SFAS 141R"), Business Combinations. SFAS 141R replaces the original SFAS No. 141. This statement applies to all transactions in which an entity obtains control of one or more businesses. SFAS 141R requires an acquirer to recognize the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at their fair values, with limited exceptions, as of the acquisition date. Goodwill is to be recognized as a residual. If the acquisition-date fair value exceeds the consideration transferred, a gain is to be recognized. The Statement generally requires that acquisition costs be expensed. This Statement is effective for business combinations for which the acquisition date is on or after January 1, 2009. We do not expect the adoption of this Statement will have a material impact on our financial position or results of operations.

In December 2007, the FASB issued SFAS No. 160 ("SFAS 160"), Noncontrolling Interests in Consolidated Financial Statements. SFAS 160 requires companies to report ownership interest in subsidiaries held by other parties (minority interest) be clearly identified, labeled and presented in the consolidated statement of financial condition separately within the equity section. The amount of consolidated net income attributable to the parent company and to the noncontrolling interest is to be clearly identified and presented on the face of the consolidated statement of income. The Statement is effective beginning January 1, 2009. We do not expect the adoption of this Statement will have a material impact on our financial position or results of operations.

In March 2008, the FASB issued Statement of Financial Accounting Standards No. 161, or SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities – an amendment of FASB Statement No. 133”. SFAS No. 161 enhances the disclosure. We do not expect the adoption of this Statement will have a material impact on our financial position or results of operations.

Presentation of share and per share information

All common stock share and per share information has been adjusted to reflect the 1 for 20 reverse stock split effective on March 14, 2007.

Page - 13 -


Results of Operations

Three-Months Ended June 30, 2008 compared June 30, 2007
The following discussion of financial results below is derived from unaudited financial statements for the three months ended June 30, 2008 and 2007.

   
Three Months Ended
June 30, 2008
 
Three Months Ended 
June 30, 2007
 
 
 
Amount
 
% of 
Revenue
 
Amount
 
% of 
Revenue
 
Service contract revenue
 
$
8,994,863
   
100.0
%
$
5,969,220
   
100.0
%
                           
HEALTHCARE EXPENSES:
                         
Salaries, wages and employee benefits
   
4,605,733
   
51.2
%
 
3,093,425
   
51.8
%
Medical expenses
   
2,643,335
   
29.4
%
 
1,505,682
   
25.2
%
Other operating expenses
   
254,269
   
2.8
%
 
246,619
   
4.1
%
Total healthcare expenses
   
7,503,337
   
83.4
%
 
4,845,726
   
81.2
%
                           
Gross profit
   
1,491,526
   
16.6
%
 
1,123,494
   
18.8
%
                           
OPERATING EXPENSES:
                         
Selling, general & administrative expenses
   
1,495,409
   
16.6
%
 
1,178,286
   
19.7
%
Depreciation and amortization
   
530,126
   
5.9
%
 
572,409
   
9.6
%
Total operating expenses
   
2,025,535
   
22.5
%
 
1,750,695
   
29.3
%
                           
Operating loss
   
(534,009
)
 
(5.9
)%
 
(627,201
)
 
(10.5
)%
                           
Net interest income and (expense)
   
39,749
   
0.4
%
 
83,949
   
1.4
%
                           
Loss before income taxes
   
(494,260
)
 
(5.5
)%
 
(543,252
)
 
(9.1
)%
                           
Income tax expense
   
   
0.0
%
 
(168,000
)
 
2.8
%
                           
Net (loss)
 
$
(494,260
)
 
(5.5
)%
$
(375,252
)
 
(6.3
)%

Net revenue, as defined earlier, from medical services provided primarily to correctional institutions for the three months ended June 30, 2008 and 2007, was $8,994,863 and $5,969,220, respectively, which represents an increase of $3,025,643 or 50.7%. The net loss was $494,260 or 5.5% of revenue and $375,252 or 6.3% of revenue for the three months ended June 30, 2008 and 2007, respectively, which represented an increased loss of $119,008.

Revenues
The improvement in revenue for the three months ended June 30, 2008 compared to the same period for the prior year resulted from the addition of new contracts since March 31, 2007, totaling $2.2 million: Henrico County, VA; Jackson County, OR; Kitsap County, WA, Yakima County Juvenile and Wicomico County MD, Chesapeake County, VA; Douglas County, OR, as well as the contracts in Oregon acquired from EMDC, P.C. in February. Together these contracts accounted for approximately $2,243,508 or 74.1% of the increase in revenue for the period. Revenue improvement totaling approximately $496,939, or 16.4% of the increase; resulted primarily from expansion of the services provided in Sedgwick County, KA; Yakima County, WA; Harford County, MD and Dorchester County, MD plus other volume related activities with a number of our existing contracts in which we were providing services prior to 2007. Price increases related to existing service requirements totaled approximately $285,196 or 9.4% of the increase.

Page - 14 -

 
Healthcare Expenses
Salaries and employee benefits
Salaries and employee benefits for healthcare employees were $4,605,733 or 51.2% of revenue for the three months ended June 30, 2008, compared to $3,093,425 or 51.8% of revenue for the three months ended June 30, 2007. The increase in spending for salaries and employee benefits of $1,512,308 or 48.9% is due to the addition of new healthcare employees required to support the increased staffing requirements resulting from our new medical service contracts and expansions in some of our existing agreements. The primary factors causing the decrease in salaries and employee benefits as a percentage of revenue was the reduction of paid overtime as a percentage of wages.
 
Medical expenses
Medical expenses for the three months ended June 30, 2008 and 2007 were $2,643,335 or 29.4% of revenue and $1,505,682 or 25.2% of revenue, respectively, which represented an increase of $1,137,653 or 75.6%. The increase in spending for medical expenses in absolute dollars reflects increases for medical services both in and out of the facility plus increased expenditures for pharmacy and radiology services. The increase in spending as a percentage of revenue results from an increase in out-of-facility expenses for hospitalization and other related expenditures primarily in Baltimore County, MD. Out-of facility medical expenses are more volatile and other healthcare expense as the number of inmates requiring hospitalization and related care in any given financial period can vary greatly.

Other operating expenses
Other operating expenses were $254,269, or 2.8% of revenue, for the three months ended June 30, 2008, compared to $246,619, or 4.1% of revenue, for the three-month period ended June 30, 2007. The increase of $7,650 in spending is directly related to the increase in the number of inmates served as a result of the new service contracts. The decrease in other medical expenses as a percentage of revenue reflects lower spending for employee advertising as well as reduced spending as a percentage of revenue for professional liability insurance.

Operating Expenses
Selling, general and administrative expenses
Selling, general and administrative expenses for the three months ended June 30, 2008 and 2007 were $1,495,409 or 16.6% of revenue and $1,178,286 or 19.7% of revenue, respectively. The increase of $317,123 or 26.9% reflects investment in additional management and administrative and management personnel required to support the Company due to the increase in service contracts as well as additional costs associated with the Company’s new headquarters at Hanover, Maryland in February 2008. Equity based compensation for the three month period ended June 30, 2008 and 2007 was $143,192 and $110,460, respectively.

Depreciation and amortization
Depreciation and amortization primarily reflects the amortization of intangible assets related to the acquisition of Conmed, Inc. in January 2007 and the purchase of medical service contracts from EMDC, P.C. in February 2008. Amortization of service contracts acquired was $422,000, or 4.7% of sales, compared to $496,000, or 8.3% of sales, respectively. The decline primarily reflects lower amortization expense for service contracts acquired as certain individual contracts become fully amortized. Amortization of non-compete agreements was $82,000, or 0.9% of sales, compared to $67,000, or 1.1% of sales, respectively. Depreciation expense increased to $26,126 compared to $9,409 due primarily to capital expenditures associate with the new corporate office .

Interest income
Interest income was $41,253 for the three months ended June 30, 2008 compared to $84,193 for the same period in 2007. Cash balances in the second quarter of 2008 were slightly higher compared to the second quarter of 2007, however the lower interest income reflects reduced short-term interest rates during the period.

Interest expense
Interest expense for the second quarter increased to $1,504 in 2008 compared to $244 in 2007.

Income tax expense
Management applied a valuation allowance against certain deferred tax assets because of a limited history of taxable income, the long-term nature of the deferred tax asset and certain limitations regarding the utilization of the net operating loss carryforwards, as a result no tax benefit has been recognized for the loss from operations for the three months ended June 30, 2008. The tax benefit of $168,000 in the second quarter of 2007 was reversed following the 338 tax election by the Company later in the year.

Page - 15 -

 
Six-Months Ended June 30, 2008 compared June 30, 2007

The following discussion of financial results below is derived from proforma unaudited financial statements for the six months ended June 30, 2008 prepared on the basis that the acquisition of Conmed was completed on December 31, 2006. The proforma adjustments were based on available information and on assumptions we believe are reasonable under the circumstances. The unaudited proforma financial information is presented for informational purposes and is based on management’s estimates. The unaudited proforma statements of operations do not purport to represent what results of operations actually would have been if the transactions set forth above had occurred on the dates indicated or what results of operations will be for future periods. Proforma adjustments include consolidation of the Company and Conmed, Inc. for the full six-month period plus an adjustment to reflect the amortization of intangible assets, which increased depreciation and amortization on the proforma unaudited financial statements by $184,000.

   
Six Months Ended
June 30, 2008
 
Six Months Ended 
June 30, 2007
 
 
 
Amount
 
% of 
Revenue
 
Amount
 
% of 
Revenue
 
Service contract revenue
 
$
16,831,113
   
100.0
%
$
11,520,159
   
100.0
%
                           
HEALTHCARE EXPENSES:
                         
Salaries, wages and employee benefits
   
8,719,760
   
51.8
%
 
5,838,464
   
50.7
%
Medical expenses
   
4,659,923
   
27.7
%
 
3,079,426
   
26.7
%
Other operating expenses
   
487,704
   
2.9
%
 
457,236
   
4.0
%
Total healthcare expenses
   
13,867,387
   
82.4
%
 
9,375,126
   
81.4
%
                           
Gross profit
   
2,963,726
   
17.6
%
 
2,145,033
   
18.6
%
                           
OPERATING EXPENSES:
                         
Selling, general & administrative expenses
   
3,084,421
   
18.3
%
 
2,153,200
   
18.7
%
Depreciation and amortization
   
1,029,575
   
6.1
%
 
1,249,350
   
10.8
%
Total operating expenses
   
4,113,996
   
24.4
%
 
3,402,550
   
29.5
%
                           
Operating loss
   
(1,150,270
)
 
(6.8
)%
 
(1,257,517
)
 
(10.9
)%
                           
Net interest income and (expense)
   
103,956
   
0.6
%
 
143,714
   
1.2
%
                           
Loss before income taxes
   
(1,046,314
)
 
(6.2
)%
 
(1,113,803
)
 
(9.7
)%
                           
Income tax (benefit)
   
   
0.0
%
 
(429,000
)
 
(3.7
)%
                           
Net (loss)
 
$
(1,046,314
)
 
(6.2
)%
$
(684,803
)
 
(5.9
)%

Net revenue, as defined earlier, from medical services provided primarily to correctional institutions for the six months ended June 30, 2008 and 2007, was $16,831,113 and $11,520,159, respectively, which represents an increase of $5,310,954 or 46.1%. The net loss was $1,046,314 or 6.2% of revenue and $684,803 or 5.9% of revenue for the six months ended June 30, 2008 and 2007, respectively, which represented an increase loss of $361,511.

Revenues
The increase in revenue for the six months ended June 30, 2008 compared to the same period for the prior year resulted from the addition of new contracts. Together these contracts accounted for approximately $4,149,143 or 78.1% of the increase in revenue for the period. Revenue improvement totaling approximately $596,097, or 11.2% of the increase; resulted primarily from expansion of the services provided plus other volume related activities with a number of our existing contracts in which we were providing services prior to 2007. Price increases related to existing service requirements totaled approximately $565,714 or 10.7% of the increase.

Page - 16 -

 
Healthcare Expenses
Salaries and employee benefits
Salaries and employee benefits for healthcare employees were $8,719,760 or 51.8% of revenue for the six month period ended June 30, 2008, compared to $5,838,464 or 50.7% of revenue for the same six month period in 2007. The increase in spending for salaries and employee benefits of $2,881,296 or 49.4% is due to the addition of new healthcare employees required to support the increased staffing requirements resulting from our new medical service contracts and expansions in some of our existing agreements.
 
Medical expenses
Medical expenses for the six months ended June 30, 2008 and 2007 were $4,659,923 or 27.7% of revenue and $3,079,426 or 26.7% of revenue, respectively, which represented an increase of $1,580,497 or 51.3%. The increase in spending for medical expenses in absolute dollars reflects increases for medical services both in and out of the facility plus increased expenditures for pharmacy and radiology services. The increase in spending as a percentage of revenue results from an increase in out-of-facility expenses for hospitalization and other related expenditures primarily in Baltimore County, MD. Out-of facility medical expenses are more volatile than other healthcare expense as the number of inmates requiring hospitalization and related care in any given financial period can vary greatly.

Other operating expenses
Other operating expenses were $487,704, or 2.9% of revenue, for the six months ended June 30, 2008, compared to $457,236, or 4.0% of revenue, for the six-month period ended June 30, 2007. The increase of $30,468 in spending is directly related to the increase in the number of inmates served as a result of the new service contracts. The decrease in other medical expenses as a percentage of revenue reflects lower spending for employee advertising as well as reduced spending as a percentage of revenue for professional liability insurance.

Operating Expenses
Selling, general and administrative expenses
Selling, general and administrative expenses for the six months ended June 30, 2008 and 2007 were $3,084,421 or 18.3% of revenue and $2,153,200 or 18.7% of revenue, respectively. The increase of $931,221 or 43.2% reflects investment in additional management and administrative personnel required to support the Company due to the increase in service contracts as well as additional costs associated with the Company’s new headquarters at Hanover, Maryland in February 2008. Equity based compensation for the six month period ended June 30, 2008 and 2007 was $263,247 and $299,449, respectively.

Depreciation and amortization
Depreciation and amortization primarily reflects the amortization of intangible assets related to the acquisition of Conmed, Inc. in January 2007 and the purchase of medical service contracts from EMDC, P.C. in February 2008. Amortization of service contracts acquired for the six months ended June 20, 2008 was $836,000, compared to $1,098,000 for the proforma six month period ended June 30, 2007. The reduced amortization primarily reflects certain individual medical service contracts that have become fully amortized. Amortization of non-compete agreements was $154,000 and $135,000. Depreciation expense increased to $39,575 compared to $16,350 due primarily to capital expenditures associate with the new corporate office.

Interest income
Interest income for the six months ended June 30, 2008 and 2007 was $107,150 and $144,229, respectively, reflecting lower short-term average interest rates for the period that were partially offset by higher cash balances.

Interest expense
Interest expense for the second quarter increased to $3,194 in 2008 compared to $515 in 2007.

Income tax expense
Management applied a valuation allowance against certain deferred tax assets because of a limited history of taxable income, the long-term nature of the deferred tax asset and certain limitations regarding the utilization of the net operating loss carryforwards, as a result no tax benefit has been recognized for the loss from operations for the six months ended June, 2008. The proforma tax benefit of $429,000 for the six months ended June 30, 2007 was reversed following the 338 tax election by the Company later in the year.

Page - 17 -


LIQUIDITY AND CAPITAL RESOURCES
 
Financing is generally provided by funds generated from our operating activities.

Cash flow for the six-month period ended June 30, 2008.
Cash as of June 30, 2008 and December 31, 2007 was $7,251,819 and $7,136,720, respectively.

Cash flows from operations totaled $668,188, reflecting $1,295,079 in adjustments for depreciation, amortization and stock based compensation to reconcile the net loss to net cash provided by working activities, plus $419,424 in changes in working capital components. The above was partially offset by the net loss of $1,046,314.

Investing activities used $517,159. The acquisition of EMDC, P.C. service contracts used $245,762 and purchases of computer and office equipment primarily related to the new office facility used $271,397.

Financing activities used $35,930 reflecting payments on a promissory note related to the EMDC,P.C. acquisition of $32,101 and $3,830 on a vehicle loan.

Liquidity
The Company finances its activities through working capital and any funds available through operations and does not maintain a line of credit.
 
Loans
As of June 30, 2008, we owed $105,000 on a promissory note outstanding with zero percent interest that is reflected on the balance sheet at $100,174 related to the EMDC, P.C. asset purchase and $9,386 on a vehicle loan.
 
Off Balance Sheet Arrangements
The Company is required to provide performance and payment guarantee bonds to county governments under certain contracts. As of June 30, 2008, the Company has two performance bonds totaling $6,864,933 and two payment bonds for $2,695,128, totaling $9,560,061. The surety issuing the bonds has recourse against the Company’s assets in the event the surety is required to honor the bonds.

Contractual Obligations
The following table presents the Company’s expected cash requirements for contractual obligations outstanding as of June 30, 2008:
 
 
 
  Total
 
Due as of
 6/30/09  
 
Due as of 
6/30/10 
and 
6/30/11  
 
Due as of 
6/30/12 
and 
6/30/13  
 
Due 
Thereafter
 
Automobile Loan
 
$
9,092
 
$
8,248
 
$
844
 
$
 
$
 
Note Payable
   
105,000
   
70,000
   
35,000
   
   
 
Equipment Leases
   
97,017
   
36,283
   
56,426
   
4,308
       
Automobile Leases
   
60,328
   
24,845
   
35,483
   
   
 
Office Space Leased
   
702,727
   
178,121
   
292,440
   
232,166
   
 
Total Contractual Cash Obligations
 
$
974,164
 
$
317,497
 
$
420,193
 
$
236,474
 
$
 
 
Effects of Inflation
The Company believes that inflation and changing prices over the past three years have not had a significant impact on its revenue or results of operations.

Page - 18 -


Potential Future Service Contract Revenue
As of June 30, 2008, the Company had entered into 30 agreements with county governments to provide medical and healthcare services to county correctional institutions. Most of these contracts are for multiple years and include option renewal periods which are, in all cases, at the county’s option. The original terms of the contracts are from one to nine years. These medical service contracts have potential future service contract revenue of $142 million as of June 30, 2008, with a weighted average term of 5.1 years, of which approximately $108 million relates to the option renewal periods.
 
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
 
The information in this Item is not being disclosed by Smaller Reporting Companies pursuant to Regulation S-K.
 
ITEM 4(T).  CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures.  Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective such that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Our internal control over financial reporting is a process designed by, or under the supervision of, our chief executive officer and chief financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes policies and procedures that pertain to the maintenance of records that in reasonable detail accurately reflect the transactions and dispositions of our assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of our financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with the authorization of our board of directors and management; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Changes in Internal Control over Financial Reporting. During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Page - 19 -


PART II.  OTHER INFORMATION
 
 ITEM 1. LEGAL PROCEEDINGS 
 
There are no material changes in the legal proceedings pending against us.
 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES
 
None
 
ITEM 3. DEFAULT UPON SENIOR SECURITIES
 
None
 
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
The Registrant held its Annual Meeting of Stockholders on October 28, 2004.
 
 
B.
Not Applicable
 
 
C.
Five directors were elected. John Pappajohn, Richard W. Turner, Edward B. Berger, Terry E. Branstad, John W. Colloton until the 2009 Annual Meeting of Stockholders or until their successors are duly elected and qualified. The minimum number of votes cast in favor of their elections was 9,844,285.
 
The second matter voted upon was the ratification of the appointment of McGladrey & Pullen, LLP as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2008. The votes cast were as follows: Votes for: 9,635,125; Votes against: 5,000; and Votes abstained: 882,351.
 
A third matter voted upon was the approval of an amendment to the Company's 2007 Stock Option/Stock Plan covering an increase of 750,000 shares to a total 2,350,000 shares. The votes cast were as follows: Votes for: 6,650,798; Votes against: 2,619,799 and Votes abstained: 139,278.
 
ITEM 5. OTHER INFORMATION
 
 None
 
ITEM 6. EXHIBITS
 
31.1
Section 302 Certification of Principal Executive Officer
31.2
Section 302 Certification of Principal Financial Officer
32.1
Section 906 Certification of Principal Executive Officer
32.2
Section 906 Certification of Principal Financial Officer

Page - 20 -

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Conmed Healthcare Management, Inc.
   
August 14, 2008
 
 
By /s/ Richard W. Turner
 
Richard W. Turner, Ph.D.
 
President and Chief Executive Officer
   
August 14, 2008
 
 
By /s/ Thomas W. Fry
 
Thomas W. Fry
 
Chief Financial Officer and Secretary

Page - 21 -

 
EX-31.1 2 v123111_ex31-1.htm
EXHIBIT 31.1

CERTIFICATIONS

I, Richard W. Turner, Ph.D. certify that:

1) I have reviewed this Quarterly Report on Form 10-Q of Conmed Healthcare Management, Inc. (the “Company”);

2)  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)  The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)) and 15d-15(f) for the Company and have:

a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;

c)  Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

5)  The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.
 
August 14, 2008   
 
By /s/ Richard W. Turner
 
Richard W. Turner, Ph.D.
 
President and Chief Executive Officer
 

 
EX-31.2 3 v123111_ex31-2.htm
EXHIBIT 31.2

CERTIFICATIONS

I, Thomas W. Fry, certify that:

1)  I have reviewed this Quarterly Report on Form 10-Q of Conmed Healthcare Management, Inc. (the “Company”);

2)  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)  The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;

c)  Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

5)  The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

August 14, 2008
 
 
By /s/ Thomas W. Fry
 
Thomas W. Fry
 
Chief Financial Officer
 
 
 

 
 
EX-32.1 4 v123111_ex32-1.htm
Exhibit 32.1

CERTIFICATION OF FINANCIAL STATEMENTS

Pursuant of 18 U.S.C. 63 1350, the President and Chief Executive Officer of Conmed Healthcare Management , Inc. (the "Company") hereby certifies that this Form 10-Q and the financial statements thereto fully comply with the requirements of Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q and the financial statements thereto fairly present, in all material respects, the financial condition and results of operations of the Company.

August 14, 2008
 
 
By /s/ Richard W. Turner
 
Richard W. Turner, Ph.D.
 
President and Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to and will be retained by Conmed Healthcare Management, Inc. and will be furnished to the Securities and Exchange Commission or its staff upon request.
 
 
 

 
 
EX-32.2 5 v123111_ex32-2.htm
Exhibit 32.2

CERTIFICATION OF FINANCIAL STATEMENTS

Pursuant of 18 U.S.C. 63 1350, the Chief Financial Officer of Conmed Healthcare Management, Inc. (the "Company") hereby certifies that this Form 10-Q and the financial statements thereto fully comply with the requirements of Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q and the financial statements thereto fairly present, in all material respects, the financial condition and results of operations of the Company.

August 14, 2008
 
 
By /s/ Thomas W. Fry
 
Thomas W. Fry
 
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to and will be retained by Conmed Healthcare Management, Inc. and will be furnished to the Securities and Exchange Commission or its staff upon request.

 
 

 
 
-----END PRIVACY-ENHANCED MESSAGE-----